Medical News | Hyperlipidemia

Editor's Choice

Emerging risk factors and risk markers for cardiovascular disease: Looking beyond NCEP ATP III

This review discusses emerging risk factors for CVD, including hs-CRP, lipoprotein(a), homocysteine, fibrinogen, homocysteine, and coronary artery calcification.

LATEST ARTICLES

Statins and cancer: Discovering their role in treating gynecologic cancers

HMG-CoA reductase inhibitors, commonly referred to as statins, have gained popularity for their ability to effectively lower cholesterol levels in patients with CV disease, but new roles for statins may be on the horizon.

First visit of a 47-year-old woman with severe hypertriglyceridemia and type 2 diabetes (CME)

First visit of a 47-year-old woman with severe hypertriglyceridemia and type 2 diabetes

Second visit of a 47-year-old woman with severe hypertriglyceridemia and type 2 diabetes (CME)

Second visit of a 47-year-old woman with severe hypertriglyceridemia and type 2 diabetes

Emerging risk factors and risk markers for cardiovascular disease: Looking beyond NCEP ATP III

This review discusses emerging risk factors for CVD, including hs-CRP, lipoprotein(a), homocysteine, fibrinogen, homocysteine, and coronary artery calcification.

Elevated CRP alone doesn't justify statin treatment

C-reactive protein (CRP) doesn't add predictive value to traditional cardiovascular risk factors, and there does not appear to be a causal association between CRP and coronary heart disease (CHD), according to results of two studies published in the July 1, 2009, issue of the Journal of the American Medical Association.